Clinuvel Pharmaceuticals (ASX:CUV) appointed specialty pharmaceutical firm Diligens Salud, part of the Scienza Group, to market and sell the Scenesse (afamelanotide) therapy in Argentina, according to a Friday filing with the Australian bourse.
The therapy, used to treat patients with erythropoietic protoporphyria, will be facilitated under maned-patient programs, with both parties collaborating on long-term formal marketing authorization, the filing said.
Erythropoietic protoporphyria is a genetic condition characterized by skin sensitivity to sunlight and artificial light.
The company's shares were up almost 1% in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。